Researchers use E.coli to make potential malaria vaccine

Dr. Nirbhay Kumar, working with Walter Reed Army Institute for Research, has found a way to use E.coli bacteria as an affordable protein critical in the potential transmission-blocking  malaria vaccine he is working on.

Dr. Nirbhay Kumar, working with Walter Reed Army Institute for Research, has found a way to use E.coli bacteria as an affordable protein critical in the potential transmission-blocking malaria vaccine he is working on.

A Tulane University researcher has found a way to use E.coli bacteria to cheaply manufacture a once hard-to-produce protein critical to the development of a potential transmission-blocking malaria vaccine.

Dr. Nirbhay Kumar, PhD, professor and chair of tropical medicine at Tulane University School of Public Health and Tropical Medicine, worked with Dr. Evelina Angov of the Walter Reed Army Institute for Research to use the common bacteria to create a new process to purify and refold protein CHrPfs25. When tested as a vaccine, the protein produced a 100 percent effective malaria transmission-blocking antibody response in mice using the two most common species of malaria-carrying mosquitoes, according to results to be published in the April issue of the journal Infection and Immunity.

Malaria, which kills nearly 800,000 people every year worldwide, is caused by a microscopic parasite that alternates between human and mosquito hosts at various stages of its lifecycle. Dr. Kumar’s vaccine seeks to trigger an immune response in people so they produce antibodies that target a protein the malaria parasite needs to reproduce within a mosquito.

“This is the central step,” Dr. Kumar said. “Malaria affects the poorest of the poor. And if you are trying to make a vaccine for those billions of people who are at risk, you need to make it cheaper to manufacture. We think that producing this protein in bacteria will make it very cost effective for large-scale vaccine production.”

The next step will be to develop a version of the vaccine that can be used in clinical trials, Dr. Kumar said.

Transmission blocking vaccines, though not yet widely tested in humans, have the potential to be used in conjunction with more traditional malaria vaccines and other interventions—such as malaria drugs and bed nets—to fight the complex tropical disease and ultimately aid in the gradual elimination of the parasites.

Dr. Kumar’s studies are funded by the National Institutes of Health.

A Tulane University researcher has found a way to use E.coli bacteria to cheaply manufacture a once hard-to-produce protein critical to the development of a potential transmission-blocking malaria vaccine.

Dr. Nirbhay Kumar, PhD, professor and chair of tropical medicine at Tulane University School of Public Health and Tropical Medicine, worked with Dr. Evelina Angov of theWalter Reed Army Institute for Research to use the common bacteria to create a new process to purify and refold protein CHrPfs25. When tested as a vaccine, the protein produced a 100 percent effective malaria transmission-blocking antibody response in mice using the two most common species of malaria-carrying mosquitoes, according to results to be published in the April issue of the journal Infection and Immunity.

Malaria, which kills nearly 800,000 people every year worldwide, is caused by a microscopic parasite that alternates between human and mosquito hosts at various stages of its lifecycle. Dr. Kumar’s vaccine seeks to trigger an immune response in people so they produce antibodies that target a protein the malaria parasite needs to reproduce within a mosquito.

“This is the central step,” Dr. Kumar said. “Malaria affects the poorest of the poor. And if you are trying to make a vaccine for those billions of people who are at risk, you need to make it cheaper to manufacture. We think that producing this protein in bacteria will make it very cost effective for large-scale vaccine production.”

The next step will be to develop a version of the vaccine that can be used in clinical trials, Dr. Kumar said.

Transmission blocking vaccines, though not yet widely tested in humans, have the potential to be used in conjunction with more traditional malaria vaccines and other interventions—such as malaria drugs and bed nets—to fight the complex tropical disease and ultimately aid in the gradual elimination of the parasites.

Dr. Kumar’s studies are funded by the National Institutes of Health.

– Keith Brannon

Advertisements

About Tulane University SPHTM

Tulane's School of Public Health and Tropical Medicine is the oldest school of public health in the country and the only American school of tropical medicine. Our mission is to advance public health knowledge, promote health and well-being, and prevent disease, disability, and premature mortality. This is accomplished through academic excellence in education of public health professionals, rigorous scientific research of public health problems, creative partnerships to advance the practice of public health, and innovative service to the local, national, and international public health community.
This entry was posted in Spring/Summer 2014 and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s